Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal vaccines.

Delia Bethell1, Andrew J Pollard

  • 1Department of Paediatrics, University of Oxford, John Radcliffe Hospital, UK.

Expert Review of Vaccines
|August 12, 2003
PubMed
Summary
This summary is machine-generated.

Meningococcal serogroup C conjugate vaccines have nearly eradicated childhood disease in the UK. Developing a serogroup B vaccine is the next challenge for eradicating invasive meningococcal disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Nature communications·2022
Same author

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Infection and immunity·2022
Same author

Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.

Human vaccines & immunotherapeutics·2022
Same author

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

The Journal of infection·2022
Same author

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

JCI insight·2022
Same author

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

JCI insight·2022
Same journal

Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model.

Expert review of vaccines·2026
Same journal

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same journal

Whole cell and acellular pertussis vaccines - rethinking the evidence.

Expert review of vaccines·2026
Same journal

Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic.

Expert review of vaccines·2026
Same journal

Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics.

Expert review of vaccines·2026
See all related articles

Area of Science:

  • Vaccinology
  • Microbiology
  • Public Health

Background:

  • Invasive meningococcal disease (IMD) is a significant public health concern with high mortality.
  • Serogroup C meningococcal conjugate vaccines have been highly effective in reducing IMD in the UK.
  • Eradication of IMD is a feasible goal with further vaccine development.

Purpose of the Study:

  • To review the impact of meningococcal serogroup C conjugate vaccines.
  • To identify challenges and opportunities in eradicating invasive meningococcal disease.
  • To highlight the need for a serogroup B meningococcal vaccine.

Main Methods:

  • Review of existing literature and immunization program data.
  • Analysis of vaccine efficacy and impact on disease epidemiology.

Related Experiment Videos

  • Exploration of current and future vaccine development strategies.

    • Main Results:

    • Near-elimination of serogroup C meningococcal disease in UK children following vaccine introduction.
    • Demonstrated feasibility of eradicating IMD through vaccination.
    • Identification of serogroup B as the primary remaining obstacle to eradication.

    Conclusions:

    • Protein-polysaccharide conjugate vaccines have revolutionized meningococcal disease prevention.
    • Development of a safe and immunogenic serogroup B vaccine is critical for IMD eradication.
    • Advances in genomics offer new avenues for identifying novel vaccine candidates.